{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-126761","form_type":"8-K","ticker":"ANVS","cik":"0001477845","company_name":"Annovis Bio, Inc.","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.549461+00:00","generated_at":"2026-05-29T05:35:07.955874+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Annovis Bio appoints William Fricker as interim CFO effective December 4, 2024","bullets":["William Fricker, 61, appointed interim CFO; most recently CFO of NeuroTrauma Sciences (Dec 2023-Apr 2024).","Previously CFO at NRX Pharmaceuticals (2020-2021), taking it public, and CAO at Immunomedics (2018-2020) until sale to Gilead.","Fricker served as independent CFO contractor for biotech firms from 2021-2023; CPA (inactive), started career at PwC.","No related-party transactions; Fricker serves on contract basis without employment agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-126761","json":"https://secwatch.observer/filing/0001104659-24-126761.json","markdown":"https://secwatch.observer/filing/0001104659-24-126761.md","text":"https://secwatch.observer/filing/0001104659-24-126761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924126761/0001104659-24-126761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1477845/000110465924126761/tm2430528d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:35:07.955874+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}